Figures & data
Table 1. Summary of patient demographics and baseline characteristics.
Figure 1. Summary of CHE scores of almost completely healed/completely healed by (A) PGA (B) PGA LOCF and almost completely healed by (C) PaGA (D) PaGA LOCF over time. Treatment could end prior to 24 weeks if a rating of clear/almost clear was achieved or if treatment was terminated early. For A and C, analyses were based on patients with observed data, patient numbers differed from visit to visit as illustrated by n values below the x axis. For B and D data presented are LOCF (n = 631). LOCF: last observation carried forward; PGA: Physician Global Assessment; PaGA: Patient Global Assessment.
Table 2. Summary of pain and itch scores.
Figure 2. Summary of (A) EQ-5D VAS and utility scores and (B) over time of EQ-5D VAS scores by PGA rating over time. Data shown are mean (2SE). EQ-5D: quality of life assessment; PGA: Physician Global Assessment; SE: standard error; VAS: visual analogue scale.
Figure 3. Evaluation of work impairment over time. Data presented are from all patients with observed data currently working. Consequently, patient sample size varies over time and is subject to potential selection bias as shown by n values below the x axis.
Figure 4. Final evaluation of efficacy and tolerability. Final evaluation of efficacy and tolerability was assessed at the closing visit.
Table 3. Summary of most common (≥1% patients) treatment-emergent AEs.